Active or Attractive? Oral Antiangiogenesis Therapy Plus EGFR Tyrosine Kinase Inhibitor in EGFR-Mutant NSCLC

Dual EGFR-vascular endothelial growth factor (EGFR-VEGF) pathway inhibition has long been studied as a strategy to enhance anticancer efficacy of EGFR tyrosine kinase inhibitor (TKI).1 In the phase 2 JO25567 study in Japan, bevacizumab plus erlotinib (B+E) prolonged progression-free survival (PFS) compared with erlotinib monotherapy (E) (median = 16.0 versus 9.7 mo).2 The overall survival (OS) was similar in two arms (median = 47.0 versus 47.4...